drugset / Trial / NCT01594866
Lexapro®'s Efficacy After Dose Escalation in Remission Study
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is the evaluation of remission rate between escitalopram 20 mg and 30 mg in patients with major depressive disorder.
Timeline
- Start
- 2012-05
- Primary completion
- 2016-06
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Escitalopram | Small molecule | 20 mg | Oral |
| Subject | Escitalopram | Small molecule | 30 mg | Oral |